BG Medicine this week announced that its board of directors has appointed Eric Bouvier as the firm's new president and CEO. The appointment became effective Jan. 9. Bouvier brings more than a decade of experience in the cardiovascular and molecular diagnostic markets. Previously, Bouvier was head of bioMerieux's immunoassay business.
Pieter Muntendam, who has served as president and CEO of BG Medicine for the past six years will now be the company's executive VP and chief medical officer.
The Personalized Medicine Coalition's board of directors has elected Stafford O'Kelly, president of Abbott Molecular, as its new chairman. David King, CEO of the Laboratory Corporation of America, is the board's treasurer. Jeffrey Cossman, president and founder of United States Diagnostic Standards, will serve as the board's secretary.
Agendia has hired Peter Wulff as its new VP of finance and chief financial officer. According to Agendia, Wulff brings to the company more than 25 years of financial management and corporate governance expertise in the life sciences industry, as well as more than 12 years of experience working at medical device companies. Wulff will split his time between Agendia's Amsterdam and Irvine, Calif., locations.